Electrochemotherapy for breast cancer patients with skin metastases

ISRCTN ISRCTN56719146
DOI https://doi.org/10.1186/ISRCTN56719146
Secondary identifying numbers N/A
Submission date
27/03/2017
Registration date
29/03/2017
Last edited
10/09/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Electrochemotherapy (ECT) is a safe skin-directed treatment for cancer which combines drug treatment with short electric pulses to the tumor. The procedure lasts 20-40 minutes and is generally performed under sedation. It generally allows for a fast recovery with low discomfort. The aims of this study are to find out how well ECT works in patients with breast cancer that has spread to the skin (cutaneous metastases), and to find out which patients have the best response to the treatment.

Who can participate?
Women (men can be also included) with skin metastases from breast cancer who are not suitable candidates for surgery, radiotherapy or systemic treatments

What does the study involve?
All participants receive ECT treatment according to routine clinical practice under general sedation or local anaesthetic, according to the amount of tumor. The patients have to stay in hospital 4-6 hours after the procedure or until the following day, according to their general conditions and specific requirements. After discharge, the patients attend outpatient clinics for regular clinical examination of treated tumors. They are asked to answer to some brief questionnaires regarding their quality of life and symptoms related to skin metastases.

What are the possible benefits and risks of participating?
Taking part in this study can have many benefits for breast cancer patients with skin metastases. Participants have the support of an experienced team of health care providers, who closely monitor the tumor response to ECT, its possible side effects as well as the disease course. Collecting information about other cancer treatments given before or after ECT could help with finding new effective treatment strategies. Finally, the information gathered will help to gain insights into patient quality of life and to improve the overall treatment of other patients with skin metastases. There are no specific risks related to this study, as the treatment is part of routine clinical practice. As such, it is expected that patients may have local side effects (skin toxicity) and, very rarely, systemic side effects (fever, lung toxicity) from the ECT treatment.

Where is the study run from?
This study is being run by the Italian Senologic Group for Electrochemotherapy (GISEL) and takes place in several hospitals across Italy.

When is the study starting and how long is it expected to run for?
April 2016 to October 2021

Who is funding the study?
Associazione Piccoli Punti Onlus (Italy)

Who is the main contact?
Dr Luca G. Campana
luca.campana@unipd.it

Study website

Contact information

Dr Luca Giovanni Campana
Scientific

Veneto Institute of Oncology IOV-IRCCS
Via Gattamelata, 64
Padova
35128
Italy

ORCiD logoORCID ID 0000-0002-8466-8459
Phone +39 (0)49 821 5526
Email luca.campana@unipd.it

Study information

Study designProspective multicenter observational study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available
Scientific titleGISEL (Gruppo Italiano Senologico per l'ELettrochemioterapia) protocol: prospective multicenter registry of breast cancer patients with skin metastases treated by electrochemotherapy
Study acronymGISEL (Italian Senologic Group for Electrochemotherapy)
Study objectivesThe primary objective of the study is to confirm the results obtained in the previous multicenter retrospective study from the GISEL group. In that study, the breast cancer patients with "luminal A-like" disease who underwent electrochemotherapy with bleomycin achieved a significantly higher complete response rate compared with other surrogate subtypes, defined according to the St. Gallen classification. (73.9% vs 54.7%, P = 0.02). In the present study the trialists intend to verify, on a large perspective series, if the rate of complete response in patients with “luminal A-like" breast cancer is significantly higher than in other subgroups.
Ethics approval(s)Veneto Institute of Oncology, Padova, Italy; Ethics Committee for Clinical Trial (Istituto Oncologico Veneto IOV-IRCCS, Padova; Comitato Etico per la Sperimentazione Clinica (CESC)), 20/02/2017, ref: CE IOV: 2017/11
Health condition(s) or problem(s) studiedCutaneous metastases from breast cancer
InterventionPatients will be enrolled based on the inclusion criteria currently employed in the clinical practice. The percentage of women with "luminal A-like" breast cancer in the previous, retrospective study was 18.4%. The trialists hypothesize to have the same patient distribution in the present study. In order to test the hypothesis of a significant difference between “luminal A-like” tumors and the other surrogate subtypes with a statistical power of 90% and a significance level of 5%, some 351 patients are required (64 in the "A luminal-like" group and 287 in the group non-"luminal A-like"). Taking into account also a 15% patient dropout, it is necessary to recruit a study population of 404 patients.

All patients will receive treatment with electrochemotherapy according to the European Standard Operating Procedures of Electrochemotherapy (ESOPE). Participating in this study involves receiving treatment with ECT under general sedation or local anaesthesia, according to the amount of skin tumor involvement; the patients will have to stay in hospital 4-6 hours after the procedure or until the following day, according to their general conditions and specific requirements. After discharge, the patients will attend the outpatient clinics for regular clinical examination of treated tumors. They will be asked to answer to some brief questionnaires regarding their quality of life and symptoms related to skin metastases. The planned follow-up time planned for each patient is 12 months leading to a total study duration of four years. After the fourth year, the database could be maintained open to further accrual in the event of insufficient patient accrual or if, based on collected data, additional research questions arise.
Intervention typeMixed
Primary outcome measure1. Local response to the treatment, assessed using clinical examination and graded according to the Response Evaluation Criteria In Solid Tumors (RECIST) at 4 and 8 weeks
2. Treatment toxicity, assessed using clinical examination and graded according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) at 1 and 2 weeks and 1, 2, 3, 6 and 12 months
Secondary outcome measures1. Local progression-free survival (LPFS), assessed using physical examination at 1, 2 , 3 , 6 and 12 months (and every 6 months thereafter)
2. Quality of life, measured using the EQ-5D questionnaire at 1 and 2 weeks, and at 1, 2, 3, 6 and 12 months
Overall study start date22/04/2016
Completion date21/10/2021

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants404
Key inclusion criteria1. Cutaneous metastases from breast cancer
2. No indication to surgical resection
3. No indication to treatment with radiotherapy
4. Ineligibility or unresponsiveness to systemic cancer treatment
5. Maximum tumor depth (from the skin layer): 3 cm
6. Patient's life expectancy greater than 4 months
7. Normal hematology, hepatic and renal function
8. Performance status (ECOG) ≤2
9. At least 18 years old
Key exclusion criteria1. History of allergic reaction to bleomycin
2. Exceeding the maximum cumulative dose of bleomycin (250,000 IU / m2)
3. Severe impairment of lung, liver or kidney function
4. History of epilepsy
5. Presence of a cardiac pacemaker
6. Serious cardiac arrhythmias
7. Pregnancy or lactation
8. Unwillingness to attend the clinic for follow-up visits
9. Impaired respiratory function or presence of pulmonary fibrosis
Date of first enrolment06/03/2017
Date of final enrolment06/03/2021

Locations

Countries of recruitment

  • Italy

Study participating centres

Veneto Institute of Oncology IOV-IRCCS
Padova
35128
Italy
University of Naples
Naples
80138
Italy
Ospedale Sant'Orsola-Malpighi
Bologna
40138
Italy
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milano
20133
Italy
IRCCS San Martino-IST
Genova
16132
Italy
Fondazione Tommaso Campanella
Catanzaro
88100
Italy
Istituto Tumori "Giovanni Paolo II"
Bari
70124
Italy
IRCCS CROB
Rionero in Vulture
85028
Italy
Istituto Dermatologico San Gallicano
Roma
00144
Italy
Istituto Tumori Napoli - Fondazione G. Pascale
Naples
80131
Italy
Ospedale Oncologico Armando Businco
Cagliari
09121
Italy
A.O.U. Citta della Salute e della Scienza di Torino
Torino
10126
Italy
Policlinico Umberto I - Università La Sapienza
Rome
00161
Italy
Humanitas Centro Catanese di Oncologia
Catania
95126
Italy

Sponsor information

Veneto Institute of Oncology IOv-IRCCS
Hospital/treatment centre

Surgical Oncology Unit
Via Gattamelata, 64
Padova
35128
Italy

University of Padova
University/education

Department of Surgery Oncology and Gastroenterology
Via Giustiniani, 2
Padova
35128
Italy

Phone +39 (0)49 8214397
Email dipartimento.discog@pec.unipd.it
Website http://www.discog.unipd.it/
Istituto Oncologico Veneto
Not defined

Funders

Funder type

Charity

Associazione Piccoli Punti Onlus (Italy)

No information available

Results and Publications

Intention to publish date15/12/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe results of this study will be presented as a research article and submitted to a high-impact peer reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Luca G. Campana (luca.campana@unipd.it).

Editorial Notes

10/09/2019: Contact details updated.